To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.By continuing to use this site you are giving us your consent to do this. +1 979 431 3500, Biotek All 1 HCRx has $6.3 billion in cumulative capital commitments with offices in Stamford (CT . Fujifilm is currently accelerating business growth of Life Sciences field and continues to aggressively invest in both capital and technology in its bio CDMO business, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. We believe that now is the right time for a strategic relationship with FDB to provide us with expert manufacturing capabilities, as needed. Our investigational T-cell therapies target difficult-to-treat Epstein-Barr virus (EBV)-driven conditions, including certain cancers and multiple sclerosis, as well as a wide range of non-EBV-associated diseases. Billingham, TS23 1LH ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. christine.jackman@fujifilm.com The facility is the newest addition to FUJIFILM Diosynth Biotechnologies global portfolio of manufacturing sites which include facilities in College Station, Texas, USA, Research Triangle Park, North Carolina, USA, Teesside, UK, and Hillerd, Denmark. Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm Fujifilm to Acquire Atara's Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD. Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of April 4, 2022, 8:01 PM UTC Share this article Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need. We are thrilled that through this acquisition we will add approximately 140 talented staff from Ataras cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business., FUJIFILM Diosynth Biotechnologies is a highly respected industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, said Pascal Touchon, president and chief executive officer, Atara. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). This information is preliminary, has not been audited, and is subject to change upon the audit of the companys financial statements for the year ended December 31, 2021. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. This press release contains or may imply forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the new sites talent, strategic location on the West Coast, and potential for future capacity growth, we are confident that we will help our partners deliver T cell and CAR-T therapies to offer patients hope.. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. Fujifilm Completes Acquisition of a Dedicated Cell Therapy This information is preliminary, has not been audited, and is subject to change upon the audit of the companys financial statements for the year ended December 31, 2021. FUJIFILM Diosynth Biotechnologies will retain 134 employees in manufacturing and quality positions at the site. The cell therapy manufacturing facility will advance FUJIFILM Diosynth Biotechnologies global CDMO manufacturing footprint to the West Coast of the United States and complements its existing locations supporting the advanced therapy market in College Station, Texas, U.S.A., Watertown, Massachusetts, U.S.A., and its recently announced BioCampus in the United Kingdom. FUJIFILM Corporation has invested over USD 5.5 billion to grow the Bio CDMO business unit in order to provide our customers with long-term support across a full-range of modalities, and manufacturing scales, said Takatoshi Ishikawa, senior executive vice president, general manager Bio CDMO Division, FUJIFILM Corporation. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. Furthermore, in order to expand the business in the most advanced biopharmaceutical fields, FUJIFILM Diosynth Biotechnologies joined Landmark Bio, the industry-academia research and development consortium,to explore the application of genetically modified cell therapies. Watertown, MA 02472 Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress. Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID: 13726583. Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID: 13726583. Beset by challenges, Atara lays off staff and slims R&D focus Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. FUJIFILM Diosynth Biotechnologies will also expand use of the Thousand Oaks site to manufacture a broader portfolio of cell therapies by leveraging the experience and expertise of the manufacturing and quality staff who transitioned to FUJIFILM Diosynth Biotechnologies. Cookies are important to the proper functioning of a site. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. Fujifilm We are incredibly proud of our world-class ATOM staff and facility and believe that this strategic partnership will meet our long-term manufacturing needs. Fujifilm Expands its Advanced Therapies CDMO Business with the The closing of the transaction, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, is expected to occur in April 2022. Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. FUJIFILM Corporation will continue to expand its bio CDMO business by leveraging its strength of being able to handle a wide variety of biopharmaceutical process development and manufacturing from clinical to commercial scale for drug products, fill & finish, and packaging. Furthermore, in order to expand the business in the most advanced biopharmaceutical fields, FUJIFILM Diosynth Biotechnologies joined Landmark Bio, the industry-academia research and development consortium, to explore the application of genetically modified cell therapies. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. The closing of the transaction, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, is expected to occur in April 2022. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. Suite 102 FUJIFILM Diosynth Biotechnologies is a highly respected, quality-focused, industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, said Pascal Touchon, President and CEO of Atara. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. About FUJIFILM Diosynth Biotechnologies 805-456-4772 Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing . For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras sale of its manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the supply agreement and meet Ataras requirements, FDBs plans for the manufacturing facility, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. Denmark Under the terms of the deal, Atara will receive USD 100 million at closing and Fujifilm plans to offer positions to approximately 140 current highly skilled manufacturing and quality staff at the site. Fujifilm is currently accelerating business growth of Life Sciences field and continues to aggressively invest in both capital and technology in its bio CDMO business, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. Access. We are incredibly proud of our world-class ATOM staff and the facility and believe that this strategic partnership will meet our long-term manufacturing needs. FUJIFILM Diosynth Biotechnologies will retain 134 employees in manufacturing and quality positions at the site. This press release contains or may imply forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras proposed sale of its ATOM manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the parties ability to consummate such transaction, including the timing thereof, the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the proposed supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the proposed supply agreement and meet Ataras requirements, FDBs potential plans for ATOM, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Leading Global rewards project planning and execution. TOKYO, April 4, 2022 FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. 2022-04-04 TOKYO, April 4, 2022 - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. http://www.businesswire.com/news/home/20220401005459/en, 1985 - 2023 BioSpace.com. Excerpt: FUJIFILM Corporation announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. for USD 100 million. 805-395-9669 Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing. Atara Biotherapeutics, Inc. (ATRA) - Yahoo Finance The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. FDB will also expand use of the Thousand Oaks site and leverage its talented staff to manufacture a broader portfolio of cell therapies. Atara Biotherapeutics Enters Strategic Manufacturing - BioSpace Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Fujifilm to Acquire Ataras Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million, Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Product Manufacturing, Transaction Expected to Result in Reduced Operating Expenses for Atara, Upon Closing, Ataras Cash Expected to Fund Planned Operations into Q4 2023, Company to Host Live Conference Call and Webcast Today at 4pm PST / 7pm EST. Healthcare Providers, https://www.businesswire.com/news/home/20220126006000/en/. Atara Biotherapeutics Announces the Completion of the Acquisition of In 2015, Atara entered into a license agreement with the Memorial Sloan Kettering Cancer Center for development, manufacturing, and more. TOKYO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. in fighting diseaseto develop transformative therapies for patients with cancer and autoimmune conditions. SOUTH SAN FRANCISCO, Calif., April 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop . For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras sale of its manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the supply agreement and meet Ataras requirements, FDBs plans for the manufacturing facility, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. Eric Hyllengren FUJIFILM Holdings America Corporation. About FUJIFILM Corporation For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. Fujifilm These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. THOUSAND OAKS, Calif., December 20, 2022 -- ( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus. Atara expects to report cash, cash equivalents and short-term investments of $371.1 million as of December 31, 2021. Morrisville, NC 27560 805-395-9669 Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. ft. manufacturing facility is currently named Atara T-cell Operations and Manufacturing (ATOM) and is readily expandable to support cell therapy manufacturing processes, including allogeneic T-cell and CAR T immunotherapies. Fujifilm to Acquire Ataras Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million, Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Product Manufacturing, Transaction Expected to Result in Reduced Operating Expenses for Atara, Upon Closing, Ataras Cash Expected to Fund Planned Operations into Q4 2023, Company to Host Live Conference Call and Webcast Today at 4pm PST / 7pm EST. An archived replay will be available on the Company's website for 30 days. Thousand Oaks, CA. Atara Biotherapeutics, Inc. ( @Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.By continuing to use this site you are giving us your consent to do this. The cell therapy manufacturing facility will advance FUJIFILM Diosynth Biotechnologies global CDMO manufacturing footprint to the West Coast of the United States and complements its existing locations supporting the advanced therapy market in College Station, Texas, U.S.A., Watertown, Massachusetts, U.S.A., and its recently announced BioCampus in the United Kingdom. INVESTORS & MEDIA: For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. | Source: We are thrilled that through this acquisition we will add approximately 140 talented staff from Ataras cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. 805-456-4772 About - T-Cell Immunotherapy Technology Platform - Atara Biotherapeutics Growing our world-class talent and knowledge in manufacturing of advanced therapies is vital to our continued success in supporting our partners in advancing tomorrows medicines, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Ataras T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California for USD 100 million upfront, retaining current manufacturing and quality staff at the site. Christine Jackman ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. Atara Biotherapeutics Announces the Completion of the Acquisition of Global Multicancer Screening Market to Reach $7.78 Billion by 2032 Fujifilm Completes Acquisition of a Dedicated Cell Therapy Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. FUJIFILM Diosynth Biotechnologies will also expand use of the Thousand Oaks site to manufacture a broader portfolio of cell therapies by leveraging the experience and expertise of the manufacturing and quality staff who transitioned to FUJIFILM Diosynth Biotechnologies. To be the leading and most trusted global Contract Development and Manufacturing Organization in the biopharmaceutical industry. FUJIFILM Diosynth Biotechnologies has existing locations in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerd, Denmark, the company is currently building new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of . +44 1642 363511, 2430 Conejo Spectrum Street Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. In connection with this announcement, Atara will host a webcast and conference call today at 4pm PST / 7pm EST.

Steven Wright Married, Articles A